In this study, we aimed to assess the cancer risk among patients with periodontal disease. Patients diagnosed with periodontal diseases at Hacettepe University between 2007 and 2012 were included and data on the diagnosis of any cancer after periodontal disease were collected from patient files. The age- and sex-standardized incidence rates (SIRs) were calculated using Turkish National Cancer Registry 2013 data. A total of 5199 patients were included. Median follow-up was 7.2 years. Patients with periodontal diseases had 17% increased risk of cancer compared with the expected counts for the corresponding age and sex groups (SIR: 1.17; 95% CI: 1.04–1.3, P = 0.006). The increased cancer risk was statistically significant in women (SIR: 1.24; 95% CI: 1.05–1.45, P = 0.008) but not in men. Among women with periodontal disease, the risks of breast cancer (SIR: 2.19) and head and neck cancer (SIR: 4.71) were significantly increased. Among men, the risks of prostate cancer (SIR: 1.84), head and neck cancer (SIR: 3.55), and hematological cancers (SIR: 1.76) were significantly increased. This study showed that periodontal diseases were associated with increased risk of several cancers. Besides other well-known benefits for health, the provision of oral/dental health should be considered and employed as a cancer prevention measure.

The treatment landscape for castration-resistant prostate cancer (mCRPC) is undergoing significant advancements, particularly with the emergence of poly(ADP-ribose) polymerase inhibitors and their ... Tweetable abstract How to determine the MAGNITUDE of benefit from poly(ADP-ribose) polymerase inhibitors? Ongoing debate on the utilization of biomarkers.

Ewing sarcoma (ES) mainly affects children and adolescents; thus, treatment protocols for adult patients are adapted from pediatric protocols. Long treatment durations often lead to treatment discontinuation for adults. This single-center retrospective study evaluated real-world outcomes and compliance with standard chemotherapy regimens in adult patients with localized ES. Adult patients diagnosed with localized ES who underwent curative intent treatment between 2007 and 2022 were retrospectively analyzed. Patients who were intended to receive the vincristine, adriamycin, and cyclophosphamide (VAC)/(ifosfamide, etoposide) regimen, consisting of 18 cycles along with local treatment, were included in this study. Adherence to the treatment protocol and outcomes were evaluated. Event-free survival (EFS) and overall survival were calculated, and predictors of treatment completion were assessed. A total of 31 patients were analyzed. Median age was 28 years (range, 18–71 yr); 17 patients were male (54.8%) and 14 were female (45.2%). Fourteen (45.1%) patients underwent surgery, 10 (32.3%) received radiotherapy, and 7 (22.5%) received both treatments. Eighteen (58.1%) patients completed 18 chemotherapy cycles. Patients undergoing surgical resection were likelier to complete all the chemotherapy cycles (odds ratio: 0.117, 95% confidence interval: 0.016–0.835). The estimated 5-year EFS and overall survival rates were 37% and 58%, respectively. Multivariate analysis identified a neutrophil-lymphocyte ratio ≥ 5 as an independent predictor of EFS (hazard ratio: 4.50, 95% confidence interval: 1.52–13.30, P = .006). Compliance with the 51-week-long vincristine, adriamycin (doxorubicin), and cyclophosphamide/ifosfamide and etoposide chemotherapy regimen remains a critical issue for adult patients. Our findings suggest that surgical resection may be associated with better compliance with the chemotherapy protocol, and a neutrophil-lymphocyte ratio of ≥5 may be linked to poorer outcomes.

Ejmi Eurasian Journal of Medical Investigation